Related Experiment Video

Updated: Dec 30, 2025

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

71.1K

Use of the triglyceride-glucose index (TyG) in cardiovascular disease patients

Javad Alizargar1, Chyi-Huey Bai2, Nan-Chen Hsieh3

  • 1Research Center for Healthcare Industry Innovation, National Taipei University of Nursing and Health Sciences, Taipei, 112, Taiwan. jaz.tmu@gmail.com.

Cardiovascular Diabetology
|January 17, 2020
PubMed

Insights

The triglyceride-glucose (TyG) index shows a link to coronary artery disease (CAD), but its use in cardiovascular disease (CVD) patients is questionable due to confounding factors like diabetes and hyperlipidemia.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Syndrome Research

Background:

  • The triglyceride-glucose (TyG) index, a marker of insulin resistance in healthy individuals, has been associated with coronary artery disease (CAD) prevalence.
  • Previous studies suggest a positive correlation between the TyG index and symptomatic CAD.
  • The clinical utility of the TyG index as a marker for atherosclerosis in cardiovascular disease (CVD) patients requires careful evaluation.

Discussion:

  • The interpretation of the TyG index in CVD patients may be confounded by diabetes mellitus and hyperlipidemic states, which are often comorbidities.
  • Fasting blood glucose and triglyceride levels, the components of the TyG index, may independently contribute to CVD risk.
  • The added clinical value of the TyG index over its constituent parameters in CVD patients needs further investigation.

Key Insights:

  • The association between the TyG index and atherosclerosis in CVD patients is potentially biased by underlying metabolic conditions.
  • Correlation does not imply causation; the TyG index's role as a direct marker of atherosclerosis in this population remains uncertain.
  • Stratification by CAD disease category does not clarify the specific role of the TyG index in CVD pathogenesis.

Outlook:

  • Further research is needed to disentangle the independent contribution of the TyG index from its components (fasting glucose, triglycerides) in CVD.
  • Studies should consider controlling for diabetes and hyperlipidemia when assessing the TyG index's predictive value in cardiovascular patients.
  • Re-evaluating the TyG index's applicability as a standalone marker for atherosclerosis in diverse cardiovascular patient populations is warranted.

Keywords:
Cardiovascular diseasesCoronary artery diseaseRisk factorsSecondary careTriglyceride-glucose index

More Related Videos

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

11.3K
Using a Combination of Indirect Calorimetry, Infrared Thermography, and Blood Glucose Levels to Measure Brown Adipose Tissue Thermogenesis in Humans04:54

Using a Combination of Indirect Calorimetry, Infrared Thermography, and Blood Glucose Levels to Measure Brown Adipose Tissue Thermogenesis in Humans

Published on: June 2, 2023

1.9K

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
521
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
735
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
517
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
477
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
538
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
3.6K